{"id":249790,"date":"2026-03-31T00:00:00","date_gmt":"2026-03-31T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0018-2024-biopharma-biosimilars-forecast-ophthalmology\/"},"modified":"2026-04-22T17:10:51","modified_gmt":"2026-04-22T17:10:51","slug":"biosbi0018-2026-biopharma-biosimilars-forecast-ophthalmology","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0018-2026-biopharma-biosimilars-forecast-ophthalmology\/","title":{"rendered":"Biosimilars &#8211; Forecast &#8211; Ophthalmology"},"content":{"rendered":"<p>In 2024, sales of branded biologics in ophthalmology exceeded $6.7 billion in the major pharmaceutical markets under study (United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, and Japan). Throughout our 2024-2034 forecast period, the reference brands Lucentis (ranibizumab),\u00a0Eylea (aflibercept), and Susvimo (ranibizumab PDS) are set to lose patent protection, and biosimilars will enter the market and erode both patient share and drug prices. We present our forecasts for these key reference brands and their biosimilars by molecule and country \/ region.<\/p>\n","protected":false},"template":"","class_list":["post-249790","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ophthalmology","biopharma-product-biosimilars","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":5,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249790\/revisions"}],"predecessor-version":[{"id":578218,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249790\/revisions\/578218"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}